



# LINCOLN PHARMACEUTICALS LIMITED



Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-6777-8000, Fax: +91-79-6777-8062.

Website: [www.lincolnpharma.com](http://www.lincolnpharma.com), E-Mail: [info@lincolnpharma.com](mailto:info@lincolnpharma.com).

## Statement of Standalone and Consolidated Audited Financial Results for the Quarter and Year ended on 31-March-2017

PART-I											(Rs. In Lacs)
Sr. No.	Particulars	Consolidated					Standalone				
		Quarter Ended			Year Ended		Quarter Ended			Year Ended	
		31/03/2017 (Audited)	31/12/2016 (Unaudited)	31/03/2016 (Audited)	31/03/2017 (Audited)	31/03/2016 (Audited)	31/03/2017 (Audited)	31/12/2016 (Unaudited)	31/03/2016 (Audited)	31/03/2017 (Audited)	31/03/2016 (Audited)
I	Revenue from Operations (Net of excise duty)	11,902.01	7,235.02	11,998.62	36,064.25	40,015.04	8,802.33	6,486.71	8,689.26	30,466.42	31,081.12
II	Other Income	61.77	119.85	852.46	289.39	736.04	-71.20	110.10	799.32	127.07	629.07
III	Total Revenue (I+II)	11,963.78	7,354.87	12,851.08	36,353.64	40,751.08	8,731.13	6,596.81	9,488.58	30,593.49	31,710.19
IV	Expenses										
(a)	Cost of Materials Consumed	2,150.31	1,875.64	2,005.65	7,819.36	7,178.70	1,440.56	1,331.37	1,569.18	5,642.60	5,578.38
(b)	Purchase of Stock-In-Trade	7,391.75	2,510.16	7,148.31	14,554.56	21,010.99	5,057.03	2,635.26	4,691.46	12,199.25	15,225.87
(c)	Changes in Inventories of Finished Goods, Work-In-Progress and Stock-In-Trade	-220.89	-629.06	209.64	-663.55	-444.56	-301.81	-542.93	187.66	-615.96	-438.90
(d)	Employee Benefits Expense	663.47	909.46	823.80	3,764.97	2,882.88	674.30	849.34	766.80	3,511.26	2,673.21
(e)	Finance Cost	176.77	134.84	408.39	699.48	996.19	145.26	101.03	106.72	541.27	553.73
(f)	Depreciation and Amortisation Expense	141.32	146.00	128.78	553.65	486.58	101.00	104.00	89.64	387.33	321.44
(g)	Other Expenses	1,480.53	1,509.37	1,511.16	5,940.87	5,333.73	1,249.03	1,428.75	1,355.71	5,506.06	4,790.74
	Total Expenses	11,783.26	6,456.41	12,235.73	32,669.34	37,444.52	8,365.37	5,906.82	8,767.17	27,171.81	28,704.47
V	Profit before exceptional and extraordinary items and tax (III - IV)	180.52	898.46	615.35	3,684.30	3,306.55	365.76	689.99	721.41	3,421.68	3,005.72
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit before extraordinary items and tax (V - VI)	180.52	898.46	615.35	3,684.30	3,306.55	365.76	689.99	721.41	3,421.68	3,005.72
VIII	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit before Tax (VII-VIII)	180.52	898.46	615.35	3,684.30	3,306.55	365.76	689.99	721.41	3,421.68	3,005.72
X	Tax Expense										
(a)	Current tax	39.06	189.13	129.13	775.03	694.40	76.81	145.36	151.52	718.55	631.22
(b)	Deferred tax	43.64	60.00	77.06	200.37	232.18	45.03	51.00	60.19	174.77	199.88
XI	Profit (loss) for the period after tax (IX - X)	97.82	649.33	409.16	2,708.90	2,379.97	243.92	493.63	509.70	2,528.36	2,174.62
	Share of Profit/(Loss) of Minority	-2.19	2.21	7.39	2.42	11.74	0.00	0.00	0.00	0.00	0.00
XII	Profit (Loss) for the period after Minority Interest	100.01	647.12	401.77	2,706.48	2,368.23	243.92	493.63	509.70	2,528.36	2,174.62
XIII	Paid-up equity share capital of face value Rs.10/- each	2,000.00	2,000.00	1,631.08	2,000.00	1,631.08	2,000.00	2,000.00	1,631.08	2,000.00	1,631.08
XIV	Reserve Excluding Revaluation Reserves				17,027.56	11,664.85				16,666.41	11,481.83
XV	Earnings Per Equity Share (Not Annualised)										
(a)	Basic	0.50	3.42	2.46	15.14	14.52	1.22	2.61	3.12	14.14	13.33
(b)	Diluted	0.50	3.42	2.40	15.14	14.16	1.22	2.61	3.05	14.14	13.01

STANDALONE AND CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES					(Rs. In Lakhs)	NOTES	
Sr. No.	Particulars	Consolidated		Standalone			
		As at 31/03/2017 (Audited)	As at 31/03/2016 (Audited)	As at 31/03/2017 (Audited)	As at 31/03/2016 (Audited)		
A	<b>EQUITY AND LIABILITIES</b>					1	The above Financial Results were reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at the meeting held on 30th May, 2017.
1	Shareholders' Funds						
	(a) Share Capital	2,000.00	1,631.08	2,000.00	1,631.08	2	The Board of Directors has recommended a dividend of Rs. 1.20 (@ 12%) per share of face value of Rs.10/- each of the Company, subject to the approval of Shareholders at the Annual General Meeting.
	(b) Reserves and Surplus	17,027.56	11,664.85	16,666.41	11,481.83		
	(c) Money received against Share Warrants	0.00	756.29	0.00	756.29		
	Sub Total - Shareholders' Fund	19,027.56	14,052.22	18,666.41	13,869.20		
2	Share application money pending allotment	0.00	0.00	0.00	0.00	3	Figures have been regrouped wherever necessary.
3	Minority interest	21.79	19.37	0.00	0.00		
4	Non-current liabilities					4	Since the revenue from different segment is less than 10% of total revenue, segment wise results are not given.
	(a) Long-term borrowings	1,768.26	2,362.34	711.09	864.68		
	(b) Deferred tax liabilities (net)	896.13	695.76	679.52	504.75		
	(c) Other long-term liabilities	346.19	316.12	346.19	316.12		
	(d) Long-term provisions	0.00	0.00	0.00	0.00		
	Sub Total - Non - current liability	3,010.58	3,374.22	1,736.80	1,685.55	5	The figure for the Quarter ended March 31, 2017 are the balancing figures between Audited figures for the year ended March 31, 2017 and published year to the date figures upto the Third Quarter Ended December 31, 2016.
5	Current Liabilities						
	(a) Short-term borrowings	4,604.93	5,262.50	4,500.24	5,006.28		
	(b) Trade payables	2,701.45	3,082.26	1,911.12	2,057.44		
	(c) Other current liabilities	1,310.93	1,510.19	1,198.67	1,355.43		
	(d) Short-term provisions	4.37	224.04	0.00	216.81		
	Sub Total - Current liability	8,621.68	10,078.99	7,610.03	8,635.96	6	Statutory Auditors has expressed an Un-Modified audit opinion.
	TOTAL-EQUITY AND LIABILITIES	30,681.61	27,524.79	28,013.24	24,190.71		
B	<b>ASSETS</b>					7	Consolidated results includes results of its subsidiaries.
1	Non-Current Assets						
	(a) Property Plant & Equipment					8	The above Financial Results for the Quarter Ended on March 31, 2017 are available on the website of the Company <a href="http://www.lincolnpharma.com">www.lincolnpharma.com</a> and on the website of the Stock Exchange <a href="http://www.bseindia.com">www.bseindia.com</a> and <a href="http://www.nseindia.com">www.nseindia.com</a>
	i. Tangible Asstes	9,347.05	8,899.31	6,805.88	6,290.91		
	ii. Intangible Assets	960.22	948.13	37.48	25.57		
	iii. Capital Work in progress	663.09	272.91	663.09	272.91		
	iv. Intangible Assets under development	0.00	0.00	0.00	0.00		
	(b) Non-current investments	0.55	0.55	1,997.70	1,997.70		
	(c) Deferred tax assets (net)	0.00	0.00	0.00	0.00		
	(d) Long-term loans and advances	2,522.98	2,661.80	2,913.05	2,166.23		
	(e) Other non-current assets	0.00	0.00	0.00	0.00		
	Sub Total - Non Current Assets	13,493.89	12,782.70	12,417.20	10,753.32	FOR LINCOLN PHARMACEUTICALS LIMITED	
2	Current Assets						
	(a) Current investments	1,020.00	0.00	1,020.00	0.00	Date: 30/05/2017 Place: Ahmedabad	MAHENDRA G. PATEL MANAGING DIRECTOR DIN: 00104706
	(b) Inventories	3,730.60	2,748.19	3,187.17	2,466.79		
	(c) Trade receivables	9,124.51	8,052.39	7,973.11	7,515.55		
	(d) Cash and cash equivalents	1,157.88	1,265.97	529.14	531.86		
	(e) Short-term loans and advances	2,154.73	2,675.53	2,886.62	2,923.20		
	(f) Other current assets	0.00	0.00	0.00	0.00		
	Sub Total - Current Assets	17,187.72	14,742.08	15,596.04	13,437.40		
	TOTAL - ASSETS	30,681.61	27,524.79	28,013.24	24,190.71		